Insider transactions

Richard S Levy

CIK 1454983 · EVP, Chief Drug Dev Officer · last filed 2026-08-04

Richard S Levy is an EVP, Chief Drug Dev Officer who has filed 106 SEC Form 4 insider transactions across 6 companies since 2009. The most recent filing, for KNSA, was dated Aug 4, 2026. Across all open-market trades the lifetime net is −$69.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $14.9M across reported positions. 43 SEC filings were submitted jointly with INCYTE CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$14.94M
Companies
6
Total Filings
106
Lifetime Open-Market Net
-$69.59M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
860 WASHINGTON STREET
3RD FLOOR
NEW YORK, NY 10014
Related Filers
INCYTE CORP — 43 joint filings, latest 2016-01-08
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KNSA Director 22,359 $76.77 $1.72M $0 15 2026-08-04
KOD Director 250 $92.91 $23.2K $44.3K 10 2026-07-02
MDGL Director 22,469 $494.75 $11.12M -$19.89M 23 2026-06-18
TARA Director 51,000 $2.69 $137.2K $127.6K 10 2026-06-16
CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted Director — $33.99 — $0 2 2021-06-04
INCY EVP, Chief Drug Dev Officer 16,926 $114.97 $1.95M -$49.87M 40 2016-01-08

Recent Filings

106 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-04 KNSA Mixed +403 $0 EDGAR
2026-07-02 KOD Grant (A) — $0 EDGAR
2026-06-18 MDGL Grant (A) +454 $0 EDGAR
2026-06-16 TARA Grant (A) — $0 EDGAR
2026-06-02 KNSA Mixed +2,799 $0 EDGAR
2026-05-22 MDGL Notice (144) −5,682 -$2.92M EDGAR
2026-05-22 MDGL Sell (S) −5,682 -$2.93M EDGAR
2026-02-24 MDGL Exer (M) +2,500 $18.4K EDGAR
2026-02-04 KNSA Mixed +683 $0 EDGAR
2026-01-26 MDGL Exer (M) +4,000 $65.8K EDGAR
Showing 1–10 of 106
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.